mTOR Inhibition/Targeting in Solid Tumours

 

 

As part of ESMO's continuous commitment to offering beneficial educational material relevant to your work and practice in order to receive your certificate, please complete the Evaluation Survey, which will take approximately 5 minutes. Please indicate which rating reflects your answer.

Questions marked with are required.

1. Did your undertaking of this E-Learning module allow you to improve your understanding of the signalling pathway defects in specific solid tumours that may result in mTOR activation and therefore a rationale for the clinical use of mTOR inhibitors? (1-not at all; 5-a lot)

2. Did your undertaking of this E-Learning module allow you to improve your understanding of the mechanism of action of mTOR inhibitors and implications on the design of clinical studies, as well as a need for valid biomarkers? (1-not at all; 5-a lot)

3. Did your undertaking of this E-Learning module allow you to improve your understanding of the toxicity profiles of mTOR inhibitors? (1-not at all; 5-a lot)

4. Please, provide your overall rating of the quality of the education offered by this E-Learning module. (1-poor; 5-excellent)

5. How would you rate the interactivity level offered in the E-Learning material? (1-poor; 5-excellent)

6. Was the information useful and relevant to your work and practice? (1-not at all; 5-completely)

7. Do you feel that the information presented was well balanced and supported by adequate evidence? (1-not at all; 5-absolutely)

8. If you would like to add your personal comments or make suggestions to improve future ESMO E-Learning material, please write in the box below: